C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis

Oncotarget

Volumn 6, Issue 6, 2015, Pages 4005-4019

  Brown, Mark A ^a   Foreman, Kenneth ^b   Harriss, June ^c   Das, Chhaya ^c   Zhu, Li ^c   Edwards, Melissa ^a,c   Shaaban, Salam ^d   Tucker, Haley ^c  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b Coferon Inc ^*  (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d ABBVIE INC   (United States)

Author keywords

Histone modifications; HSP90; Lysine methylation; SMYD3; Tumorigenesis

Indexed keywords

HEAT SHOCK PROTEIN 90; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE SMYD3; UNCLASSIFIED DRUG; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; SMYD3 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TETRATRICOPEPTIDE REPEAT; 3T3 CELL LINE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NIH 3T3 CELLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; TRANSFECTION;

EID: 84924233570     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2970     Document Type: Article

References (50)

1. Jenuwein T, Allis CD. Translating the Histone Code. Science. 2001; 293:1074-80.
2. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007; 447:407-12.
3. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007; 14:1025-40.
4. Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S, Tucker P. Structural and Functional Profiling of the Human Histone Methyltransferase SMYD3. PLoS ONE. 2011; 6:1-12.
5. Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G, Annan R, Sage J, Garcia BA, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 2012; 7:340-3.
6. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004; 6:731-40.
7. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y. The Lysine 831 of Vascular Endothelial Growth Factor Receptor 1 Is a Novel Target of Methylation by SMYD3. Cancer Research. 2007; 67:10759-65.
8. Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y, Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene. 2008; 27:2686-92.
9. Du SJ, Tan X, Zhang J. SMYD proteins: Key regulators in skeletal and cardiac muscle development and function. See comment in PubMed Commons below Anat Rec. 2014; 297:1650-62.
10. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006; 97:113-8.
11. Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, Furukawa Y, Nakamura Y. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005; 37:1104-7.
12. Wang H, Liu Y, Tan W, Zhang Y, Zhao N, Jiang Y, Lin C, Hao B, Zhao D, Qian J, Lu D, Jin L, Wei Q, et al. Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking. Cancer Sci. 2008; 99:787-91.
13. Brown MA, Zhu L, Schmidt C, Tucker PW. Hsp90-from signal transduction to cell transformation. Biochem Biophys Res Commun. 2007; 363:241-6.
14. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5:761-72.
15. Jarosz DF, Lindquist S. Hsp90 and Environmental Stress Transform the Adaptive Value of Natural Genetic Variation. Science. 2010; 330:1820-4.
16. Erlejman AG, Lagadari M, Toneatto J, Piwien-Pilipuk G, Galigniana MD. Regulatory role of the 90-kDa-heat-shock protein (Hsp90) and associated factors on gene expression. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2014; 1839:71-87.
17. Sollars V, Lu X, Xiao L, Wang X, Garfinkel MD, Ruden DM. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat Genet. 2003; 33:70-4.
18. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10:537-49.
19. Leinhart K, Brown M. SET/MYND Lysine Methyltransferases Regulate Gene Transcription and Protein Activity. Genes. 2011; 2:210-8.
20. Sirinupong N, Brunzelle J, Doko E, Yang Z. Structural Insights into the Autoinhibition and Posttranslational Activation of Histone Methyltransferase SmyD3. Journal of Molecular Biology. 2011; 406:149-59.
21. Xu S, Wu J, Sun B, Zhong C, Ding J. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding. Nucleic Acids Research. 2011; 39:4438-49.
22. Veraksa A, Kennison J, McGinnis W. DEAF-1 function is essential for the early embryonic development of Drosophila. Genesis. 2002; 33:67-76.
23. Spadaccini R, Perrin H, Bottomley MJ, Ansieau S, Sattler M. Structure and functional analysis of the MYND domain. J Mol Biol. 2006; 358:498-508.
24. Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D, Lary J, Cole J, Dauter Z, Minor W, Speck NA, Bushweller JH. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell. 2006; 9:249-60.
25. Wang L, Li L, Zhang H, Luo X, Dai J, Zhou S, Atadja P, Lu C, Li E, Zhao K. Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation. Journal of Biological Chemistry. 2011; 286:38725-37.
26. Jiang Y, Sirinupong N, Brunzelle J, Yang Z. Crystal Structures of Histone and p53 Methyltransferase SmyD2 Reveal a Conformational Flexibility of the Autoinhibitory C-Terminal Domain. PLoS ONE. 2011; 6:e21640.
27. Blatch GL, Lässle M. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. BioEssays. 1999; 21:932-9.
28. Sanchez ER. Hsp56: a novel heat shock protein associated with untransformed steroid receptor complexes. J Biol Chem. 1990; 265:22067-70.
29. Wu B, Li P, Liu Y, Lou Z, Ding Y, Shu C, Ye S, Bartlam M, Shen B, Rao Z. 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci U S A. 2004; 101:8348-53.
30. Owens-Grillo JK, Czar MJ, Hutchison KA, Hoffmann K, Perdew GH, Pratt WB. A Model of Protein Targeting Mediated by Immunophilins and Other Proteins That Bind to hsp90 via Tetratricopeptide Repeat Domains. Journal of Biological Chemistry. 1996; 271:13468-75.
31. Ratajczak T, Carrello A. Cyclophilin 40 (CyP-40), Mapping of Its hsp90 Binding Domain and Evidence That FKBP52 Competes with CyP-40 for hsp90 Binding. Journal of Biological Chemistry. 1996; 271:2961-5.
32. Abu-Farha M, Lanouette S, Elisma F, Tremblay V, Butson J, Figeys D, Couture JF. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. Journal of Molecular Cell Biology. 2011; 3:301-8.
33. Lee BJ, Cansizoglu AE, Süel KE, Louis TH, Zhang Z, Chook YM. Rules for Nuclear Localization Sequence Recognition by Karyopherin Beta 2. Cell. 2006; 126:543-58.
34. Pearl LH, Prodromou C. Structure and in vivo function of Hsp90. Current Opinion in Structural Biology. 2000; 10:46-51.
35. Buchner J. Hsp90 & Co.-a holding for folding. Trends in Biochemical Sciences. 1999; 24:136-41.
36. Luo X-G, Xi T, Guo S, Liu Z-P, Wang N, Jiang Y, Zhang TC. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life. 2009; 61:679-84.
37. Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of Histone Methyltransferase SMYD3 for Estrogen Receptor-mediated Transcription. Journal of Biological Chemistry. 2009; 284:19867-77.
38. Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, Chluba J, Langsley G, Weitzman JB. SMYD3 Promotes Cancer Invasion by Epigenetic Upregulation of the Metalloproteinase MMP-9. Cancer Research. 2012; 72:810-20.
39. Patki JM, Pawar SS. HSP90: chaperone-me-not. Pathol Oncol Res. 2013; 19:631-40.
40. Luo X-G, Ding Y, Zhou Q-F, Ye L, Wang S-Z, Xi T. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells. Journal of Bioscience and Bioengineering. 2007; 103:444-50.
41. He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z, Cai M, Xu K, Zeng Y, Li H, Wang J. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Human Pathology. 2012; 43:1425-35.
42. Allan R, Ratajczak T. Versatile TPR domains accommodate different modes of target protein recognition and function. Cell Stress and Chaperones. 2011; 16:353-67.
43. Gallo LI, Lagadari M, Piwien-Pilipuk G, Galigniana MD. The 90-kDa Heat-shock Protein (Hsp90)-binding Immunophilin FKBP51 Is a Mitochondrial Protein That Translocates to the Nucleus to Protect Cells against Oxidative Stress. Journal of Biological Chemistry. 2011; 286:30152-60.
44. Galigniana MD, Erlejman AG, Monte M, Gomez-Sanchez C, Piwien-Pilipuk G. The hsp90-FKBP52 Complex Links the Mineralocorticoid Receptor to Motor Proteins and Persists Bound to the Receptor in Early Nuclear Events. Molecular and Cellular Biology. 2010; 30:1285-98.
45. Frank B, Hemminki K, Wappenschmidt B, Klaes R, Meindl A, Schmutzler RK, Bugert P, Untch M, Bartram CR, Burwinkel B. Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer. International Journal of Cancer. 2006; 118:2917-8.
46. Yuan Y, Wang Q, Paulk J, Kubicek S, Kemp MM, Adams DJ, Shamji AF, Wagner BK, Schreiber SL. A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma. ACS Chemical Biology. 2012; 7:1152-7.
47. Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, Dong A, Barsyte D, Kozieradzki I, Senisterra G, Chau I, Siarheyeva A, Kireev DB, Jadhav A, et al. Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a. Journal of Medicinal Chemistry. 2009; 52:7950-3.
48. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10:537-49.
49. Webb CF, Bryant J, Popowski M, Allred L, Kim D, Harriss J, Schmidt C, Miner CA, Rose K, Cheng HL, Griffin C, Tucker PW. The ARID Family Transcription Factor Bright Is Required for both Hematopoietic Stem Cell and B Lineage Development. Molecular and Cellular Biology. 2011; 31:1041-53.
50. Reyes JC, Muchardt C, Yaniv M. Components of the Human SWI/SNF Complex Are Enriched in Active Chromatin and Are Associated with the Nuclear Matrix. The Journal of Cell Biology. 1997; 137:263-74.